Pharmala Biotech Holdings (XCNQ:MDMA) Price-to-Tangible-Book : 10.83 (As of May. 23, 2025)

Pharmala Biotech Holdings Price-to-Tangible-Book Chart

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24	Feb25
Price-to-Tangible-Book	Get a 7-Day Free Trial										-	-	85.00	280.00	15.00

Competitive Comparison of Pharmala Biotech Holdings's Price-to-Tangible-Book

For the Biotechnology subindustry, Pharmala Biotech Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Price-to-Tangible-Book falls into.

Pharmala Biotech Holdings Price-to-Tangible-Book Calculation

Pharmala Biotech Holdings's price-to-tangible-book ratio for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Pharmala Biotech Holdings Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description